← back to search

Eric M. Pridgen

Massachusetts Institute of Technology · US
Area of research
Biomaterials · Molecular Biology
Research interest
Research interests include Nanotechnology, In vivo, DNA, Cisplatin, RNA interference, and Small interfering RNA.
h-index
citations
2,143
works
9
NIH funding
primary concept
email

Recent publications

Hybrid lipid–polymer nanoparticles for sustained siRNA delivery and gene silencing
Nanomedicine Nanotechnology Biology and Medicine 2014cited by 98position: middledoi
Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery
Science Translational Medicine 2013cited by 392position: firstdoi
Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug
Proceedings of the National Academy of Sciences 2013cited by 332position: middledoi
Microfluidic Platform for Combinatorial Synthesis and Optimization of Targeted Nanoparticles for Cancer Therapy
ACS Nano 2013cited by 234position: middledoi
Nanoparticle Encapsulation of Mitaplatin and the Effect Thereof on<i>In Vivo</i>Properties
ACS Nano 2013cited by 91position: middledoi
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine
Advanced Drug Delivery Reviews 2012cited by 468position: middledoi
DNA Self‐Assembly of Targeted Near‐Infrared‐Responsive Gold Nanoparticles for Cancer Thermo‐Chemotherapy
Angewandte Chemie International Edition 2012cited by 349position: middledoi
DNA Self‐Assembly of Targeted Near‐Infrared‐Responsive Gold Nanoparticles for Cancer Thermo‐Chemotherapy
Angewandte Chemie 2012cited by 105position: middledoi
Synergistic Cytotoxicity of Irinotecan and Cisplatin in Dual-Drug Targeted Polymeric Nanoparticles
Nanomedicine 2012cited by 74position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Omid C. Farokhzad · Brigham and Women's Hospital9 papers (2012–2014)Jinjun Shi · Brigham and Women's Hospital4 papers (2012–2014)Róbert Langer · Laboratoire d’immunologie intégrative du cancer4 papers (2012–2013)Jun Wu · Kunming Medical University4 papers (2012–2014)Stephen J. Lippard · Massachusetts Institute of Technology3 papers (2012–2013)Rohit Karnik · Massachusetts Institute of Technology3 papers (2012–2013)Xiaoyang Xu · New Jersey Institute of Technology3 papers (2012–2014)Zeyu Xiao · Massachusetts Institute of Technology2 papers (2012–2012)Jillian Frieder · Baylor University2 papers (2012–2012)Pedro M. Valencia · Massachusetts Institute of Technology2 papers (2012–2013)Changwei Ji · Nanjing University of Chinese Medicine2 papers (2012–2012)Philip W. Kantoff · Memorial Sloan Kettering Cancer Center2 papers (2012–2013)Archana Swami · Massachusetts Institute of Technology2 papers (2012–2014)Brian Perea · Arizona State University1 papers (2012–2012)Christopher J. Sweeney · Harvard University1 papers (2012–2012)Nora Kulak · Massachusetts Institute of Technology1 papers (2013–2013) · 1 papers (2013–2013)Xi Zhu · The University of Sydney1 papers (2014–2014)Bruce R. Zetter · University of Michigan–Ann Arbor1 papers (2014–2014)Alexander R. Votruba · Case Western Reserve University1 papers (2014–2014)